Journal
SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-021-96879-3
Keywords
-
Categories
Funding
- National Science Foundation [BCS-2035114]
- National Institutes of Health [3UL1TR001422-06S4]
- Northwestern University Office of Research
Ask authors/readers for more resources
The two-dose mRNA vaccines against SARS-CoV-2 are effective in preventing COVID-19 infection, but there is a decline in antibody levels and reduced neutralization of emerging variants three months post-vaccination, indicating the need to identify correlates of clinical protection for booster vaccination timing and indications.
Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available